

GAU1643  
GI 5298A**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Ioannis Moutsatosos et al.

FOR: GENETICALLY ENGINEERED CELLS WHICH EXPRESS BONE MORPHOGENETIC PROTEINS

SERIAL NO.: 09/148,234 GROUP ART UNIT: 1643

DATE OF FILING: September 9, 1998 EXAMINER: Not yet assigned

#5/a  
12/19/98  
me**CERTIFICATE OF MAILING**

Assistant Commissioner for Patents  
Washington, D.C. 20231  
BOX: (NON-FEE AMENDMENT)

I hereby certify that the following paper is being deposited with the United States Postal Service as First Class Mail service pursuant to 37 C.F.R. § 1.8(a) in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on October 6, 1998

Hanovskaya  
Name of Signing Person

**PRELIMINARY AMENDMENT**

Sir:

Before prosecution of the above-identified patent application, please amend the specification as follows:

**IN THE SPECIFICATION:**

Page 3, in the section "BRIEF DESCRIPTION OF THE DRAWINGS", line 9, after "[i.p. ).5, 1.0 µg/day, 20 d]", please delete "

"Figure 1 shows the results of a grip test of muscle strength. Figure 2 shows bone induction by femoral trabecular bone volume (TBV). Figure 3 shows the osteoblastic differentiation of CFU-f represented by alkaline phosphatase histochemistry (ALP). Figure 4 shows the cellular proliferation of CFU-f represented by BrdU. Figure 5 shows the cellular apoptosis of CFR-f cells represented by DAPI staining. Figure 6 shows the cellular apoptosis of CFR-f cells represented by Annexin V-FITC and PI-staining" and replace with

RECEIVED  
98 OCT 14 AM 7:49  
GROUP 180